Study provides additional evidence on hepatitis D virus prevalence in people without hepatitis B
18.11.2026 10:59:27 EET | HUS | Press release
The established medical understanding has been that hepatitis D virus infection cannot occur without a simultaneous hepatitis B infection. The results from a study conducted by HUS and the University of Helsinki suggest that hepatitis D virus infection can occur without a simultaneous hepatitis B infection.

Hepatitis D (HDV) is a satellite virus, which means that it needs a helper virus for transmission. The current understanding is that HDV cannot be transmitted without a simultaneous hepatitis B (HBV) infection. However, this view has been challenged in some recent studies. A study conducted by HUS and the University of Helsinki provided additional evidence on the prevalence of HDV without an HBV infection.
“Based on the results, we cannot conclude that HDV can occur without HBV, but the evidence we gained is very interesting. If it can be demonstrated that HDV can occur without HBV, further research will be needed to determine the clinical significance of HDV without HBV,” explains Satu Kurkela, head of division and a specialist in clinical microbiology at HUS.
Hepatitis B, C and D are blood-borne infections. Hepatitis B and C can cause severe liver diseases if the infections become chronic. The current understanding is that an HDV infection predisposes an HBV carrier to severe symptoms of the disease.
More research needed on other possible helper viruses
The study analyzed 2,121 samples of blood serum and plasma from 1,996 patients. The samples analyzed were residual specimens from samples sent to the HUS Virology and Immunology laboratory for other diagnostic purposes in 2021 and 2022.
In the analyzed samples, 20 patients were positive for HDV antibodies, and 17 of them did not have a simultaneous HBV infection. One patient was diagnosed with an active HDV infection without an HBV infection. This patient was diagnosed with hepatitis C (HCV).
“This finding was especially interesting, because there is previous evidence suggesting that HCV may be a possible HDV helper virus. Our finding does not provide certainty on the matter, and more research is needed,” says Jussi Hepojoki, a researcher at the University of Helsinki.
The helper virus defines which cells HDV can penetrate in the body.
“Information on what other helper viruses HDV can use would be virologically significant. Especially, as we know that HDV may significantly aggravate HBV infection.”
First data on HDV prevalence in Finland
The study provided information on the prevalence of HDV in Finland for the first time. In the analyzed material, the prevalence was about one percent.
“This does not mean that one percent of Finns carry HDV, but it provides initial information on the occurrence of the virus in Finland,” says Hanna Jarva, chief physician and specialist in clinical microbiology at HUS.
Currently, HDV antibodies are only examined from people who have been diagnosed with HBV. If it is true that HDV can also occur without HBV, some HDV infections may remain undetected.
“Hopefully, future research will show if this really is the case, and, if so, what its clinical significance is.”
The study was published in the Journal of Clinical Virology.
Research article: Further evidence of hepatitis D occurring in the absence of hepatitis B
In university hospitals, research is part of the treatment: new findings make treatment practises more efficient and help target treatments correctly. We work in close collaboration with the University of Helsinki and other universities, and we publish about 3000 peer-reviewed research articles annually.
Today’s research provides better care tomorrow.
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
Contacts
Satu KurkelaHead of Division, Specialist in Clinical MicrobiologyHUS
Tel:050 4284183satu.kurkela@hus.fiHanna JarvaChief Physician, Specialist in Clinical MicrobiologyHUS
Tel:050 4279816hanna.jarva@hus.fiJussi HepojokiResearcherthe University of Helsinki
Tel:050 4482866jussi.hepojoki@helsinki.fiImages

About HUS
HUS Helsinki University Hospital is the biggest provider of specialized healthcare in Finland. Our high expertise is internationally recognized and accredited. As a university hospital, we are on the cutting edge of developing and evaluating our treatment methods and activities.
HUS treats 700,000 patients every year. Our 26,500 professionals work to provide the best possible care for our patients. We are responsible for organizing specialized health care in the Uusimaa region. The treatment of many rare and difficult diseases in Finland has been centralized to HUS as well.
HUS – Leading healthcare
The HUS media service is available for the media Mon–Thu 10:00 a.m.–4:00 p.m. and Fri 10:00 a.m.–3:00 p.m., tel. 050 427 2875, or via e-mail: viestinta@hus.fi.
hus.fi/en
Alternative languages
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Största delen av dem som avled i hjärnblödning hann aldrig få neurokirurgisk vård17.11.2026 08:25:15 EET | Pressmeddelande
I en internationell studie som leddes av HUS neurokirurgi observerades att mer än 70 procent av dem som avled i subaraknoidalblödning inte hann få neurokirurgisk vård. Störst är andelen i glesbygden.
Valtaosa aivoverenvuotoon kuolleista ei koskaan päässyt neurokirurgiseen hoitoon17.11.2026 08:25:15 EET | Tiedote
HUSin neurokirurgian johtamassa kansainvälisessä tutkimuksessa havaittiin, että yli 70 prosenttia lukinkalvonalaiseen aivoverenvuotoon kuolleista ei ollut päässyt neurokirurgiseen hoitoon. Osuus oli suurin syrjäseuduilla.
Most people who died from a brain hemorrhage never received neurosurgical treatment17.11.2026 08:25:15 EET | Press release
An international study led by HUS Neurosurgery discovered that more than 70 percent of those who died from a subarachnoid hemorrhage never made it to neurosurgical treatment. The proportion was highest in remote areas.
Sammanslutningens styrelse beslutade om HUS-sammanslutningens budgetförslag för 202716.11.2026 11:53:41 EET | Pressmeddelande
Sammanslutningens styrelse beslutade för egen del om HUS-sammanslutningens budgetförslag för 2027 och ekonomiplanen för 2027–2029.
Yhtymähallitus päätti HUS-yhtymän vuoden 2027 talousarvioesityksestä16.11.2026 11:53:41 EET | Tiedote
Yhtymähallitus päätti omalta osaltaan HUS-yhtymän vuoden 2027 talousarvioesityksestä sekä taloussuunnitelmasta vuosille 2027–2029.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom